ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1147

Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response
Abstract Number: 1148

GWAS Identified New Genes in Synovial Fibroblasts Linked to Early Remission in RA
Abstract Number: 1149

A Novel Mitochondrial Variant as a Predictor for the Rapid Progressive Knee Osteoarthritis Phenotype: Development of a Predictive Model and Functional Studies
Abstract Number: 1150

Spatial Transcriptomics Stratifies Health and Psoriatic Disease Severity by Emergent Cellular Ecosystems
Abstract Number: 1151

Colonic Organoids to Study the Role of HLA-B27 in Gastrointestinal Epithelial Biology
Abstract Number: 1152

A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases
Abstract Number: 1153

Differentially Expressed Genes in Males and Females with Ankylosing Spondylitis (AS): Transcriptomics of IL-17-producing Cells in Patients with AS
Abstract Number: 1154

Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
Abstract Number: 1155

Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
Abstract Number: 1156

Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
Abstract Number: 1157

Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Abstract Number: 1158

Differential Plasma Levels of S100 Proteins in Male versus Female Patients with Ankylosing Spondylitis
Abstract Number: 1159

Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Abstract Number: 1160

Mapping Spondyloarthritis Susceptibility Loci in B10.RIII Mice
Abstract Number: 1161

IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].